Product Details
| Product Name: Gliclazide | CAS No.: 21187-98-4 |
| EC-No.: 244-260-5 | Min. Order: 1kg |
| Purity: 98%min | Supply Ability: 1000kg |
| Release date: 2025/10/24 |
Gliclazide is an oral prescription medication used to treat Type 2 diabetes. It belongs to a class of drugs known as sulfonylureas. Its primary function is to stimulate the pancreas to release more insulin, thereby helping to lower blood sugar levels.
It is not used for Type 1 diabetes, where the body does not produce insulin at all.
How Does It Work? (Mechanism of Action)
Gliclazide works through two main mechanisms:
Stimulates Insulin Secretion: It binds to specific receptors on the beta cells of the pancreas. This action prompts the closure of potassium channels, which leads to the opening of calcium channels. The influx of calcium stimulates these cells to release insulin into the bloodstream.
Extra-Pancreatic Effects: Some studies suggest it may also improve the body's sensitivity to insulin and reduce glucose production in the liver, though its primary effect remains insulin secretion.
Important Note: For Gliclazide to work, the patient must still have functioning beta cells in their pancreas capable of producing insulin.
Key Uses and Benefits
Management of Type 2 Diabetes: It is used as part of a treatment plan that includes diet, exercise, and weight loss. It is prescribed when these lifestyle changes alone are not sufficient to control blood glucose levels.
Cardiovascular Benefits (Proposed): Some studies, particularly with the modified-release (MR) formulation, suggest that Gliclazide may have a neutral or potentially beneficial effect on cardiovascular health compared to some other sulfonylureas. It may also offer antioxidant properties.
Low Risk of Severe Hypoglycemia: Compared to older sulfonylureas (like glibenclamide), Gliclazide is associated with a lower risk of causing dangerously low blood sugar (hypoglycemia), especially its modified-release version, which provides a more steady release of the drug.
Available Formulations
Gliclazide comes in two main forms:
Immediate-Release (IR) Tablets: Typically taken once or twice daily.
Modified-Release (MR) Tablets: Designed to release the medication slowly throughout the day. This allows for once-daily dosing, provides more stable blood sugar control, and may further reduce the risk of hypoglycemia.
Important Side Effects and Risks
Like all medications, Gliclazide can cause side effects. The most common and serious ones include:
Hypoglycemia (Low Blood Sugar): This is the most common serious side effect. Symptoms can include:
Shakiness, dizziness, sweating
Hunger, headache
Confusion, irritability
Rapid heartbeat
In severe cases, loss of consciousness or seizure
Gastrointestinal Issues: Nausea, indigestion, diarrhea, or constipation.
Skin Reactions: Rash and itching may occur.
Weight Gain: This is a common side effect with sulfonylureas as insulin promotes fat storage.
Rare but Serious: Blood disorders (e.g., thrombocytopenia) and liver problems are very rare but possible.
Key Considerations and Precautions
Not for Everyone: It is contraindicated in people with Type 1 diabetes, diabetic ketoacidosis, or severe kidney or liver disease.
Alcohol Warning: Alcohol can both increase the risk of hypoglycemia and cause a disulfiram-like reaction (flushing, nausea, vomiting).
Drug Interactions: Many drugs can interact with Gliclazide, including other diabetes medications, certain antibiotics (e.g., fluconazole), beta-blockers, and non-steroidal anti-inflammatory drugs (NSAIDs). It's crucial to inform your doctor of all medications you are taking.
Pregnancy and Breastfeeding: Generally not recommended. The management of diabetes during pregnancy requires specialist care, often with insulin therapy.
In summary, Gliclazide is a well-established and effective oral medication for managing Type 2 diabetes by boosting the body's own insulin production. It is valued for its once-daily dosing option (MR) and relatively favorable safety profile regarding hypoglycemia risk compared to other drugs in its class.



Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $29.00/500mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-20 | |
| $0.00/25KG |
VIP6Y
|
Sichuan Zhuoyu Yantang Technology Co., Ltd.
|
2025-09-18 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-04-07 | |
| $10.00/1KG |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-06 | |
| $1.00/1g |
Apeloa production Co.,Limited
|
2024-06-27 | ||
| $0.00/1Kg/Bag |
VIP5Y
|
Sinoway Industrial co., ltd.
|
2024-06-27 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-03 | |
| $0.00/1kg |
Kindchem(Nanjing)Co.,Ltd
|
2024-01-02 | ||
| $150.00/1KG |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-10-10 |
- Since: 2006-04-03
- Address: Room 2015, No.2 Building Kaixin Mansion, No.107 Jinqiao Ave, Wuhan, China
+8613986145403
info@fortunachem.com

China